Fatal coronary vasospasm following oral triptan intake
Abstract
UNLABELLED: Triptans, commonly used for migraine treatment, induce vasoconstriction by activating 5HT1B/1D and 5HT1F receptors. Although several cases of coronary vasospasm associated with sumatriptan have been reported, few describe life-threatening arrhythmias and cardiac arrest. We present a case of fatal coronary vasospasm caused by triptan use in a young patient with minimal cardiovascular risk. A 30-year-old man with morbid obesity was admitted for unstable angina. He reported chest pain episodes starting one month earlier, coinciding with the initiation of oral sumatriptan for migraines. On the second day of hospitalization, he took 100 mg of sumatriptan. Ninety minutes later, he developed recurrent chest pain that progressed to cardiac arrest caused by a ventricular arrhythmia storm. Left anterior descending artery vasospasm with ST-segment elevation myocardial infarction was identified, and intracoronary nitrate and adenosine relieved the spasm. However, resuscitation was ineffective due to morbid obesity, leaving the patient in profound cardiogenic shock, followed by distributive shock from prolonged low-flow time. Despite maximal hemodynamic support, he succumbed to multiorgan failure. This case highlights the potentially fatal cardiovascular risk of triptans, even in low-risk patients, and underscores the need to discontinue triptans at the first sign of chest pain.
LEARNING OBJECTIVES: Coronary vasospasm, a rare but severe complication of triptans, can lead to…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.